Ascendis Pharma A/S
ASNDDrugs in Pipeline
10
Phase 3 Programs
4
Upcoming Catalysts
6
Next Catalyst
Feb 25, 2026
7dMarket Overview
Stock performance and key metrics
6 upcoming, 0 past
FDA PDUFA Date TransCon hGH (standard)
For pediatric growth hormone deficiency. BLA filing. Extracted from SEC filing: 6-K
Source5 more catalysts beyond 14 days
Start a 48h free trial to see all upcoming catalysts
Once weekly subcutaneous injection of TransCon hGH
Growth Hormone Deficiency, Pediatric
TransCon CNP
Achondroplasia
Lonapegsomatropin
Growth Hormone Deficiency
TransCon hGH
Growth Hormone Deficiency, Pediatric
TransCon IL-2 β/γ
Advanced Solid Tumor
ACP-001 (TransCon hGH)
Adult Growth Hormone Deficiency
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections
Achondroplasia
ACP-001
Growth Hormone Deficiency (GHD)
Navepegritide
Achondroplasia
Somatropin
Turner Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Once weekly subcutaneous injection of TransCon hGH | Phase 3 | Growth Hormone Deficiency, Pediatric | - | - |
TransCon CNP | Phase 3 | Achondroplasia | - | - |
Lonapegsomatropin | Phase 3 | Growth Hormone Deficiency | - | - |
TransCon hGH | Phase 3 | Growth Hormone Deficiency, Pediatric | - | - |
TransCon IL-2 β/γ | Phase 2 | Advanced Solid Tumor | - | - |
ACP-001 (TransCon hGH) | Phase 2 | Adult Growth Hormone Deficiency | - | - |
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections | Phase 2 | Achondroplasia | - | - |
ACP-001 | Phase 2 | Growth Hormone Deficiency (GHD) | - | - |
Navepegritide | Phase 2 | Achondroplasia | - | - |
Somatropin | Phase 2 | Turner Syndrome | - | - |
Achondroplasia
3 drugs in this indication
Growth Hormone Deficiency (GHD)
1 drug in this indication
Adult Growth Hormone Deficiency
1 drug in this indication
Growth Hormone Deficiency, Pediatric
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)